149 related articles for article (PubMed ID: 20484992)
21. Structural insights into interacting mechanism of ID1 protein with an antagonist ID1/3-PA7 and agonist ETS-1 in treatment of ovarian cancer: molecular docking and dynamics studies.
Muthu K; Panneerselvam M; Jayaraman M; Topno NS; Das AA; Ramadas K
J Mol Model; 2012 Nov; 18(11):4865-84. PubMed ID: 22714536
[TBL] [Abstract][Full Text] [Related]
22. Differential role of Id1 in MLL-AF9-driven leukemia based on cell of origin.
Man N; Sun XJ; Tan Y; García-Cao M; Liu F; Cheng G; Hatlen M; Xu H; Shah R; Chastain N; Liu N; Huang G; Zhou Y; Sheng M; Song J; Yang FC; Benezra R; Nimer SD; Wang L
Blood; 2016 May; 127(19):2322-6. PubMed ID: 26944543
[TBL] [Abstract][Full Text] [Related]
23. FOXO3a induces differentiation of Bcr-Abl-transformed cells through transcriptional down-regulation of Id1.
Birkenkamp KU; Essafi A; van der Vos KE; da Costa M; Hui RC; Holstege F; Koenderman L; Lam EW; Coffer PJ
J Biol Chem; 2007 Jan; 282(4):2211-20. PubMed ID: 17132628
[TBL] [Abstract][Full Text] [Related]
24. E47 and Id1 interplay in epithelial-mesenchymal transition.
Cubillo E; Diaz-Lopez A; Cuevas EP; Moreno-Bueno G; Peinado H; Montes A; Santos V; Portillo F; Cano A
PLoS One; 2013; 8(3):e59948. PubMed ID: 23555842
[TBL] [Abstract][Full Text] [Related]
25. Mutation analysis of genes that control the G1/S cell cycle in melanoma: TP53, CDKN1A, CDKN2A, and CDKN2B.
Soto JL; Cabrera CM; Serrano S; López-Nevot MA
BMC Cancer; 2005 Apr; 5():36. PubMed ID: 15819981
[TBL] [Abstract][Full Text] [Related]
26. Epigenetic regulation of p14ARF and p16INK4A expression in cutaneous and uveal melanoma.
Venza M; Visalli M; Biondo C; Lentini M; Catalano T; Teti D; Venza I
Biochim Biophys Acta; 2015 Mar; 1849(3):247-56. PubMed ID: 25497382
[TBL] [Abstract][Full Text] [Related]
27. Synergism between DNA methylation and macroH2A1 occupancy in epigenetic silencing of the tumor suppressor gene p16(CDKN2A).
Barzily-Rokni M; Friedman N; Ron-Bigger S; Isaac S; Michlin D; Eden A
Nucleic Acids Res; 2011 Mar; 39(4):1326-35. PubMed ID: 21030442
[TBL] [Abstract][Full Text] [Related]
28. Frequent epigenetic silencing of the CpG island promoter of RASSF1A in thyroid carcinoma.
Schagdarsurengin U; Gimm O; Hoang-Vu C; Dralle H; Pfeifer GP; Dammann R
Cancer Res; 2002 Jul; 62(13):3698-701. PubMed ID: 12097277
[TBL] [Abstract][Full Text] [Related]
29. MicroRNA-29b is involved in the Src-ID1 signaling pathway and is dysregulated in human lung adenocarcinoma.
Rothschild SI; Tschan MP; Federzoni EA; Jaggi R; Fey MF; Gugger M; Gautschi O
Oncogene; 2012 Sep; 31(38):4221-32. PubMed ID: 22249264
[TBL] [Abstract][Full Text] [Related]
30. Gene methylation in gastric cancer.
Qu Y; Dang S; Hou P
Clin Chim Acta; 2013 Sep; 424():53-65. PubMed ID: 23669186
[TBL] [Abstract][Full Text] [Related]
31. Common BRAF(V600E)-directed pathway mediates widespread epigenetic silencing in colorectal cancer and melanoma.
Fang M; Hutchinson L; Deng A; Green MR
Proc Natl Acad Sci U S A; 2016 Feb; 113(5):1250-5. PubMed ID: 26787892
[TBL] [Abstract][Full Text] [Related]
32. IL-1β Promotes Stemness of Tumor Cells by Activating Smad/ID1 Signaling Pathway.
Lu L; Wang P; Zou Y; Zha Z; Huang H; Guan M; Wu Y; Liu G
Int J Med Sci; 2020; 17(9):1257-1268. PubMed ID: 32547321
[No Abstract] [Full Text] [Related]
33. ID1 and ID3 regulate the self-renewal capacity of human colon cancer-initiating cells through p21.
O'Brien CA; Kreso A; Ryan P; Hermans KG; Gibson L; Wang Y; Tsatsanis A; Gallinger S; Dick JE
Cancer Cell; 2012 Jun; 21(6):777-92. PubMed ID: 22698403
[TBL] [Abstract][Full Text] [Related]
34. Overexpression of ID1 promotes tumor progression in penile squamous cell carcinoma.
Hu X; Chen M; Li Y; Wang Y; Wen S; Jun F
Oncol Rep; 2019 Feb; 41(2):1091-1100. PubMed ID: 30535485
[TBL] [Abstract][Full Text] [Related]
35. Differential expression of the cyclin-dependent kinase inhibitors p16 and p21 in the human melanocytic system.
Wang Y; Becker D
Oncogene; 1996 Mar; 12(5):1069-75. PubMed ID: 8649798
[TBL] [Abstract][Full Text] [Related]
36. ID1-induced p16/IL6 axis activation contributes to the resistant of hepatocellular carcinoma cells to sorafenib.
Niu LL; Cheng CL; Li MY; Yang SL; Hu BG; Chong CCN; Chan SL; Ren J; Chen GG; Lai PBS
Cell Death Dis; 2018 Aug; 9(9):852. PubMed ID: 30154433
[TBL] [Abstract][Full Text] [Related]
37. Status of RASSF1A in uveal melanocytes and melanoma cells.
Calipel A; Abonnet V; Nicole O; Mascarelli F; Coupland SE; Damato B; Mouriaux F
Mol Cancer Res; 2011 Sep; 9(9):1187-98. PubMed ID: 21788308
[TBL] [Abstract][Full Text] [Related]
38. Expression and significance of p53, rb, p21/waf-1, p16/ink-4a, and PTEN tumor suppressors in canine melanoma.
Koenig A; Bianco SR; Fosmire S; Wojcieszyn J; Modiano JF
Vet Pathol; 2002 Jul; 39(4):458-72. PubMed ID: 12126149
[TBL] [Abstract][Full Text] [Related]
39. Involvement of SMRT corepressor in transcriptional repression by the vitamin D receptor.
Kim JY; Son YL; Lee YC
Mol Endocrinol; 2009 Feb; 23(2):251-64. PubMed ID: 19098224
[TBL] [Abstract][Full Text] [Related]
40. Expression of genes involved in the regulation of p16 in psoriatic involved skin.
Mark EB; Jonsson M; Asp J; Wennberg AM; Mölne L; Lindahl A
Arch Dermatol Res; 2006 Apr; 297(10):459-67. PubMed ID: 16552541
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
